宫颈癌和子宫内膜癌患者血清可溶性白细胞介素-2受体（sIL-2R）检测：初步数据
Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
作者信息
Ferdeghini M, Gadducci A, Prontera C, Marrai R, Malagnino G, Annicchiarico C, Fioretti P, Bianchi R
机构信息
Istituto di Medicina Nucleare, Università di Pisa, Italy.
出版信息
Anticancer Res. 1993 May-Jun;13(3):709-13.
Pretreatment serum levels of soluble interleukin-2 receptor (sIL-2R), CA 125, and SCC were measured in 183 patients with malignant or benign uterine diseases. Serum sIL-2R levels were higher in the 46 patients with cervical cancer (p < 0.05) or in the 35 patients with endometrial cancer (p < 0.05) than in the 102 patients with benign uterine diseases. Raised serum concentrations of sIL-2R (> or = 50 U/mL), CA 125 (> or = 35 U/mL) and SCC (> or = 2 ng/mL) were found in 50.0%, 15.0% and 67.5% of 40 patients with squamous cell carcinoma of the cervix, respectively. Serum sIL-2R values were > or = 50 U/mL in 83.3% of 6 patients with cervical adenocarcinoma. Elevated serum levels of sIL-2R, CA 125 and SCC were detected in 51.4%, 11.3% and 14.3% of 35 patients with endometrial cancer, respectively. The sensitivity of SCC for squamous cell carcinoma of the cervix was better than that of sIL-2R. On the other hand, we observed that sIL-2R was the most sensitive antigen for endometrial cancer; therefore it could represent a new tumor marker for the management of patients with this malignancy.
对183例患有恶性或良性子宫疾病的患者检测了可溶性白细胞介素-2受体（sIL-2R）、CA 125和鳞状细胞癌抗原（SCC）的预处理血清水平。46例宫颈癌患者（p < 0.05）或35例子宫内膜癌患者（p < 0.05）的血清sIL-2R水平高于102例良性子宫疾病患者。在40例宫颈鳞状细胞癌患者中，分别有50.0%、15.0%和67.5%的患者血清sIL-2R（≥50 U/mL）、CA 125（≥35 U/mL）和SCC（≥2 ng/mL）浓度升高。6例宫颈腺癌患者中有83.3%的患者血清sIL-2R值≥50 U/mL。在35例子宫内膜癌患者中，分别有51.4%、11.3%和14.3%的患者检测到血清sIL-2R、CA 125和SCC水平升高。SCC对宫颈鳞状细胞癌的敏感性优于sIL-2R。另一方面，我们观察到sIL-2R是子宫内膜癌最敏感的抗原；因此，它可能代表一种用于管理这种恶性肿瘤患者的新肿瘤标志物。
Zotero 插件